Gossamer Bio, Inc. (GOSS)
| Market Cap | 39.19M -84.7% |
| Revenue (ttm) | 55.54M -55.4% |
| Net Income | -180.40M |
| EPS | -0.78 |
| Shares Out | 234.70M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 15,662,354 |
| Open | 0.1700 |
| Previous Close | 0.1619 |
| Day's Range | 0.1658 - 0.1800 |
| 52-Week Range | 0.1400 - 3.8700 |
| Beta | 2.00 |
| Analysts | Hold |
| Price Target | 4.46 (+2,570.66%) |
| Earnings Date | Aug 4, 2026 |
About GOSS
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup comp... [Read more]
Financial Performance
In 2025, Gossamer Bio's revenue was $48.47 million, a decrease of -57.74% compared to the previous year's $114.70 million. Losses were -$170.37 million, 201.4% more than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for GOSS stock is "Hold." The 12-month stock price target is $4.46, which is an increase of 2,570.66% from the latest price.
News
Gossamer Bio Proxy statement: Proxy filing
Gossamer Bio filed a proxy statement on June 9, 2026, providing details for shareholder voting and corporate governance matters.
Gossamer Bio announces early tender results, early settlement of solicitation
Gossamer Bio (GOSS) announced the early tender results of its previously announced exchange offer to exchange any and all of its 5.00% Convertible Senior Notes due 2027 for a pro…
Gossamer Bio, Inc. Announces Early Tender Results and Early Settlement for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (NASDAQ: GOSS) (the “Company” or “Gossamer”), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatme...
Gossamer Bio announces extension of early tender date for exchange offer
Gossamer Bio (GOSS) extended the early tender date until 5:00 p.m., New York City time, on June 2, 2026 with respect to its previously announced exchange offer and consent solicitation…
Gossamer Bio, Inc. Announces Extension of Early Tender Date for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (NASDAQ: GOSS) (the “Company” or “Gossamer”), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatme...
Investors Sue Gossamer Bio (GOSS) Over Inflated High Blood Pressure Study Claims
A class action lawsuit was filed against biopharmaceutical company Gossamer Bio ($GOSS) on March 31, 2026. The federal securities lawsuit alleges that plaintiffs acquired Gossamer stock at artificiall...
Goldman Sachs suspends rating on Gossamer Bio
Goldman Sachs analyst Paul Choi suspended the firm’s investment rating, price target and earnings estimates for Gossamer Bio (GOSS). Given the “going concern” warning within its financials and uncerta...
Gossamer Bio price target lowered to 28c from 30c at Barclays
Barclays analyst Eliana Merle lowered the firm’s price target on Gossamer Bio (GOSS) to 28c from 30c and keeps an Underweight rating on the shares. The company’s exchange offer for…
Gossamer Bio Earnings Call Transcript: Q1 2026
Phase III PROSERA data showed clinically meaningful improvements in PAH, supported by robust CT-FRI imaging evidence of multi-compartment lung remodeling. Cost reductions and a convertible note exchange have extended cash runway and improved capital structure, with NDA submission targeted for September 2026.
Gossamer Bio Quarterly report: Q1 2026
Gossamer Bio has published its Q1 2026 quarterly earnings report on May 18, 2026.
Gossamer Bio Earnings release: Q1 2026
Gossamer Bio released its Q1 2026 earnings on May 18, 2026, summarizing the period's financial results.
Gossamer Bio Slides: Q1 2026
Gossamer Bio has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 18, 2026.
Gossamer Bio Proxy statement: Proxy filing
Gossamer Bio filed a proxy statement on May 18, 2026, providing details for shareholder voting and corporate governance matters.
Gossamer Bio Proxy statement: Proxy filing
Gossamer Bio filed a proxy statement on May 18, 2026, providing details for shareholder voting and corporate governance matters.
Gossamer Bio launches exchange offer, consent solicitation
Gossamer Bio (GOSS) commenced an exchange offer to exchange any and all of its 5.00% Convertible Senior Notes due 2027 for a pro rata portion of up to $72.0 million…
Gossamer Bio reports Q1 EPS (20c) vs. (16c) last year
Reports Q1 revenue $17M vs. $9.9M last year. “We are executing across multiple fronts at Gossamer,” said Faheem Hasnain, Chairman, Co-Founder, and CEO of Gossamer Bio (GOSS). “We have secured…
Gossamer Bio sees cash runway into 1Q27
Cash, cash equivalents and marketable securities totaled $99.2 million as of March 31, 2026. We expect the combination of current cash, cash equivalents and marketable securities will be sufficient to...
Gossamer Bio, Inc. Launches Exchange Offer and Consent Solicitation Intended to Eliminate Over $120 Million of Debt with Existing Noteholder Support
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (NASDAQ: GOSS) (the “Company”), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonar...
Gossamer Bio Announces First Quarter 2026 Financial Results and Provides Business Update
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of...
Gossamer Bio to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 18, 2026
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of...
Gossamer Bio Proxy statement: Proxy filing
Gossamer Bio filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Gossamer Bio Proxy statement: Proxy filing
Gossamer Bio filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
GOSS Stockholders Have Rights – If You Lost Money Investing in Gossamer Bio, Inc. Contact Robbins LLP for Information About Recovering Your Losses
SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Gossamer Bio, Inc. (NASDAQ: ...
Gossamer Bio, Inc. (GOSS) Securities Fraud: Contact Berger Montague To Discuss Your Rights
Philadelphia, Pennsylvania--(Newsfile Corp. - April 20, 2026) - National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer" ...
Gossamer Bio downgraded to Neutral from Overweight at Cantor Fitzgerald
Cantor Fitzgerald on Friday downgraded Gossamer Bio (GOSS) to Neutral from Overweight without a price target The firm cites the negative Phase 3 readout for PROSERA and an unclear regulatory…